Physician profile
Harold Brody
NPI 1679530802
$2,516.27
in general payments reported to CMS, 2019-2025
19 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $232 · 2021: $261 · 2022: $373 · 2023: $281 · 2024: $584 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $412.68 | 2019-2022 | |
| Abbvie INC. | $403.04 | 2020-2024 | Alloderm |
| Regeneron Healthcare Solutions, INC. | $242.48 | 2021-2025 | Dupixent |
| Genzyme Corporation | $210.04 | 2019-2024 | |
| Leo Pharma INC. | $158.69 | 2019-2022 | |
| Incyte Corporation | $156.21 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $124.02 | 2019-2025 | |
| Galderma Laboratories, L.P. | $120.58 | 2019-2025 | Dysport, Aklief |
| E.R. Squibb & Sons, L.L.C. | $115.92 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $101.88 | 2019-2020 | |
| Almirall LLC | $94.56 | 2019-2024 | Seysara |
| Janssen Biotech, INC. | $93.35 | 2019-2023 | Remicade, Stelara, Simponi |
| Ucb, INC. | $68.80 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $54.78 | 2019-2025 | Ebglyss, Taltz |
| Merz North America, INC. | $48.32 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $33.79 | 2025 | |
| Lnhc, INC | $18.57 | 2025 | Zelsuvmi |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.